SciClone Pharmaceuticals, Inc. announced that it anticipates 2014 sales revenue of $130 million to $135 million, representing an approximate 30% increase of its core business revenue (the core business revenue excludes all Sanofi products and certain Pfizer products, including Adriamycin and Daunoblastina).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.42 HKD | +0.55% | +0.55% | +32.33% |
05-16 | Sciclone Pharmaceuticals Limited Announces Change of Address of Principal Place of Business in Hong Kong | CI |
04-18 | Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31 | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+32.33% | 1.42B | |
-2.91% | 89.01B | |
-4.34% | 37.79B | |
-17.08% | 31.22B | |
+59.95% | 26.1B | |
-22.15% | 14.25B | |
-9.36% | 12.8B | |
-11.39% | 11.65B | |
-46.06% | 10.88B | |
+3.45% | 8.7B |
- Stock Market
- Equities
- 6600 Stock
- News SciClone Pharmaceuticals (Holdings) Limited
- SciClone Pharmaceuticals, Inc. Provides Sales Revenue Guidance for 2014